Skip to main content
AKBA
NASDAQ Life Sciences

Akebia 10-Q: $36.9M Q3 Revenue, $14.4M Net Loss, and a 2027 Vafseo Revenue Warning

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.52
Mkt Cap
$192.506M
52W Low
$0.542
52W High
$2.145
52W Position info
4.1% below low
Off High info
76% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

AKBA is trading near its 52-week low of $0.542 (4.1% below the low).

Summary

Akebia's Q3 10-Q confirms $36.9 million of revenue and a $14.4 million net loss, and adds that Vafseo revenue is expected to drop significantly in 2027 when TDAPA ends, with the two-year runway contingent on refinancing the BlackRock term loan.


Key Events · Earnings and Guidance · AKBA

  • Q3 Revenue Falls 37% on Auryxia Generics

    Total revenue was $36.9 million versus $58.8 million a year earlier; Auryxia net product revenue dropped to $20.0 million from $42.5 million while Vafseo was roughly flat at $14.8 million versus $14.3 million.

  • Net Loss of $14.4 Million

    The quarter swung to a $14.4 million net loss from $0.5 million of net income a year earlier, including a $1.3 million restructuring charge; the nine-month net loss was $32.3 million.

  • 2027 Vafseo Revenue Expected to Drop Sharply

    TDAPA reimbursement ends December 31, 2026, and Akebia expects to price Vafseo within the ESA range in 2027, so revenue is expected to decrease significantly versus 2026 despite higher unit volume.

  • Runway Contingent on Refinancing BlackRock Debt

    Cash was $159.3 million at September 30, 2026; the stated two-year runway assumes refinancing the term loan, whose interest-only period ends December 31, 2026 and which has $50.6 million of principal due in 2027.


Analysis · AKBA · Life Sciences

The headline numbers match this morning's earnings release, but the full 10-Q carries two things the press release did not spell out. First, Akebia expects Vafseo revenue to fall significantly in 2027 versus 2026: the TDAPA add-on payment ends December 31, 2026, and the company plans to reprice Vafseo toward the much lower ESA range even though unit volumes should rise. Second, the stated two-year cash runway is explicitly contingent on refinancing the BlackRock term loan, whose interest-only period ends December 31, 2026 and which carries $50.6 million of principal due in 2027. With $159.3 million of cash, a $32.3 million nine-month net loss, and a Nasdaq bid-price deficiency already disclosed, the equity story now hinges on the 2027 Vafseo pricing reset and the debt refinancing rather than on the quarter itself.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AKBA was trading at $0.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.5M. The 52-week trading range was $0.54 to $2.15. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AKBA - Latest Insights

AKBA
Nov 16, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.4739
Real-time Price: $0.410 info
Change: -$0.0639 (-13%) info
Market Cap: $117.257M info
AKBA
Nov 05, 2026, 7:10 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.69337
Real-time Price: $0.410 info
Change: -$0.28337 (-41%) info
Market Cap: $117.257M info
AKBA
Nov 05, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.69337
Real-time Price: $0.410 info
Change: -$0.28337 (-41%) info
Market Cap: $117.257M info
AKBA
Oct 26, 2026, 9:20 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.5765
Real-time Price: $0.410 info
Change: -$0.1665 (-29%) info
Market Cap: $117.257M info
AKBA
Oct 23, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5745
Real-time Price: $0.410 info
Change: -$0.1645 (-29%) info
Market Cap: $117.257M info